In collaboration with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), Zymedi is conducting this trial to evaluate the safety and dosage of ZMA001. This initiative follows a Cooperative Research & Development Agreement (CRADA) established between the two organizations, signifying a commitment to advancing the development of ZMA001.

PAH affects approximately 3 persons per 100,000 globally, with a significant number of new cases diagnosed annually in the U.S. Current treatments for PAH alleviate symptoms but do not address the underlying cause of the condition. ZMA001, a first-in-class therapeutic antibody, targets the novel pro-inflammatory factor KARS1 specific to monocytes and macrophages, aiming to improve survival rates and quality of life for PAH patients.

Dr. Sunghoon Kim, CEO and Founder of Zymedi, expressed enthusiasm for this milestone, stating, "Initiating the first in human trial of ZMA001 is a significant achievement for our company and the fight against PAH. We are committed to systematically assessing the safety and tolerability of ZMA001 through dose escalation trials, with the goal of establishing recommended dosage and determining the Maximum Tolerated Dose (MTD) for future clinical trials involving patients."

The trial aims to provide valuable insights into the potential of ZMA001 as a treatment for PAH, offering hope for improved outcomes for patients suffering from this debilitating condition.